Abcam, ab249639, Anti-Mad2L1 antibody [EPR9852] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Mad2L1 antibody. Carrier free. Suitable for WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR9852,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249639 is the carrier-free version of
ab171084
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Mad2L1 also known as MAD2 or Kirk Mad2 is an important player in the mitotic checkpoint ensuring proper chromosomal segregation during cell division. It acts as a spindle assembly checkpoint protein weighing approximately 24.5 kDa. It is widely expressed in tissues with high proliferative activity including testis thymus and fetal liver. In these locations Mad2L1 binds to other mitotic checkpoint proteins to control the metaphase-anaphase transition.
Biological function summary
Mad2L1 serves as an essential component of the mitotic checkpoint complex. It forms a complex with other proteins such as Mad1 BubR1 and Cdc20 inhibiting the anaphase-promoting complex/cyclosome (APC/C). This interaction prevents the premature separation of sister chromatids by blocking the degradation of securin and cyclin B. These actions ensure that cells do not progress to anaphase until all chromosomes are correctly attached to the mitotic spindle.
Pathways
Mad2L1 interacts with proteins that regulate the spindle assembly checkpoint pathway and the cell cycle. It holds particular prominence within the mitotic spindle assembly checkpoint where it regulates progression from metaphase to anaphase through its interaction with proteins like Cdc20 and BubR1. Mad2L1 also plays a role in the DNA damage response cycle highlighting its importance in maintaining genomic stability.
Mad2L1 shows significant connections with cancer and chromosomal instability syndromes. Overexpression or dysfunction of Mad2L1 can lead to chromosomal instability contributing to carcinogenesis. Studies also suggest associations with BubR1 a protein whose expression frequently correlates with Mad2L1 in various cancers. These connections highlight Mad2L1 as a potential target for therapeutic intervention in oncology.